Diagnostic utility of CYFRA 21-1 and carcinoembryonic antigen as a tumour markers in malignant pleural effusions Source: Eur Respir J 2001; 18: Suppl. 33, 397s Year: 2001
Diagnostic utility of pleural CEA and CYFRA 21-1 for malignant pleural effusions Source: Eur Respir J 2003; 22: Suppl. 45, 60s Year: 2003
Clinical significance of CEA, NSE, CYFRA 21-1 in serum and pleural fluid for the diagnosis of malignant pleural effusion associated with primary lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 528s Year: 2004
CEA, Cyfra 21.1 and NSE levels in malignant and benign pleural effusion Source: Eur Respir J 2002; 20: Suppl. 38, 273s Year: 2002
Tumor markers (TM) CEA, CYFRA 21-1,MCA and NSE in pleural effusion(PE) at malignant mezothelioma and metastatic tumor of pleura Source: Eur Respir J 2002; 20: Suppl. 38, 439s Year: 2002
The diagnostic value of the examination of the tumor markers CYFRA 21-1, NSE, TPA and CEA from the bronchoalveolar lavage fluid in diffuse pulmonary disorders Source: Annual Congress 2008 - Role of bronchoalveolar lavage in studying the pathophysiology of interstitial lung disease Year: 2008
Clinical evaluation of NSE, CYFRA 21-1, CEA and MCA at patients (pts.) with metastatic pleural effusion (PE) Source: Eur Respir J 2005; 26: Suppl. 49, 448s Year: 2005
Evaluation of pleural fluid levels and pleural-serum ratio of the tumor markers CEA, CA 15,3, CA 19,9, CA 72,4, CA 125 and CYFRA 21,1 in the diagnosis of malignant pleural effusion Source: Annual Congress 2010 - Current issues in malignant pleural diseases Year: 2010
The usefulness of Cyfra 21-1 as a disease marker in malignant pleural mesothelioma (MPM) Source: Eur Respir J 2006; 28: Suppl. 50, 85s Year: 2006
The diagnostic value of CA-125 in pleural effusions Source: Eur Respir J 2001; 18: Suppl. 33, 386s Year: 2001
Comparative evaluation of CA-125, CA 19-9, CA 15-3 and CEA in exudative benign and malignant pleural effusion Source: Annual Congress 2010 - Novel approach in diagnosis and treatment of pleural effusions Year: 2010
Utility of serum soluble mesothelin as a follow-up marker in patients with malignant pleural mesothelioma Source: Annual Congress 2007 - Biology of thoracic malignancies Year: 2007
Prognostic significance of serum and pleural mesothelin in malignant pleural mesothelioma (MPM) Source: International Congress 2017 – Mesothelioma and malignant pleural disease Year: 2017
Diagnostic value and prognostic significance of pleural C-reactive protein in lung cancer with malignant pleural effusions Source: Annual Congress 2012 - Instructive clinical aspects of thoracic oncology Year: 2012
Use of carcinoembryonic antigen in pleural effusion for differential diagnosis of benign and malignant pleural effusion Source: Annual Congress 2008 - Diagnostic aspects in thoracic oncology Year: 2008
Diagnostic value of procalcitonin and C-reactive protein in the differentiation among bening and malignant pleural effusion Source: Annual Congress 2009 - Diagnosis of pleural effusions and rare tumours experience Year: 2009
Importance of tumour markers CYFRA 21-1 and NSE serum concentration values in diagnosis and esteem of nonmicrocelullar lung cancer expansion Source: Eur Respir J 2005; 26: Suppl. 49, 325s Year: 2005
Diagnostic value of CYFRA 21-1, CEA, CA19-9, CA 15-3, and CA 125 assay in pleural effusions: analysis of 116 cases and review of the literature Source: Eur Respir J 2005; 26: Suppl. 49, 73s Year: 2005
Diagnostic usefulness of tumour markers in pleural effusions Source: Annual Congress 2009 - Diagnosis of pleural effusions and rare tumours experience Year: 2009
Diagnostic value of common MAGE RT-PCR in malignant pleural effusion Source: Eur Respir J 2002; 20: Suppl. 38, 273s Year: 2002